Less Ads, More Data, More Tools Register for FREE

LONDON BROKER RATINGS: Jefferies rates Future at 'hold'; Spirent upped

Wed, 15th Mar 2023 09:36

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

----------

FTSE 100

----------

Berenberg cuts AstraZeneca price target to 12,400 (12,600) pence - 'buy'

----------

JPMorgan raises Relx price target to 2,840 (2,810) pence - 'overweight'

----------

FTSE 250

----------

Berenberg raises Spirent Communications to 'buy' (hold) - price target 250 (300) pence

----------

Berenberg cuts Future price target to 1,780 (2,600) pence - 'buy'

----------

Jefferies starts Future with 'hold' - price target 1,300 pence

----------

JPMorgan reinitiates Petershill Partners with 'overweight' - price target 246 pence

----------

JPMorgan reinitiates Intermediate Capital with 'neutral' - price target 1,451 pence

----------

JPMorgan raises TP ICAP price target to 235 (210) pence - 'overweight'

----------

RBC cuts Close Brothers price target to 1,200 (1,250) pence - 'outperform'

----------

RBC cuts Direct Line price target to 180 (190) pence - 'sector perform'

----------

Deutsche Bank cuts Genuit price target to 378 (447) pence - 'buy'

----------

SMALL CAP

----------

Deutsche Bank cuts IQE rice target to 40 (60) pence - 'buy'

----------

Berenberg cuts Johnson Service price target to 155 (180) pence - 'buy'

----------

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Astrazeneca Relx Future TP ICAP Close Bros Genuit Group IQE Johnson Service

Shares in this article

Related News

AstraZeneca breast cancer drug camizestrant shows "sustained" benefit
18 hours ago

AstraZeneca breast cancer drug camizestrant shows "sustained" benefit

(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.

BSF Enterprise shares jump on paper in praise of "T-rex leather"
19 hours ago

BSF Enterprise shares jump on paper in praise of "T-rex leather"

(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather product...

Moderna and other groups get $60 million to develop Ebola vaccine
1 day ago

Moderna and other groups get $60 million to develop Ebola vaccine

* CEPI commits just over $60 million to three vaccine groups